Clinical Trial Update: ACP-103 to Treat Parkinson's Disease [Phase 2]

View source ↗

Summary

NINDS reports the completion of a Phase 2 trial evaluating ACP-103 for Parkinson's disease and associated dyskinesias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesias
• Parkinson Disease

Drugs mentioned

• ACP-103 (pimavanserin)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Parkinson's Disease, Dyskinesias | Phase 2 | Status: COMPLETED